Journal
TRANSPLANTATION AND CELLULAR THERAPY
Volume 29, Issue 3, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtct.2022.12.010
Keywords
Severe Aplastic Anemia; Haploidentical Family Donor; Pediatric; Young adults; Thiotepa; Melphalan; Abatacept
Categories
Ask authors/readers for more resources
Allogenic hematopoietic cell transplantation (HCT) is the best curative approach for severe aplastic anemia (SAA), and HCT from haploidentical family donors (HFDs) has become a feasible option for patients lacking an HLA-identical donor. However, there is limited data on HFD-HCT for young SAA patients. A multicenter retrospective study evaluated the outcomes of 79 SAA patients undergoing HFD-HCT and found that PTCy-based HFD-HCT is a reasonable option for young patients with high-risk SAA, and optimization of conditioning and GVHD prophylaxis may further improve outcomes. The use of abatacept was found to have a favorable impact on GVHD and event-free survival (EFS).
Allogenic hematopoietic cell transplantation (HCT) is the best curative approach for patients with severe aplastic anemia (SAA). The outcomes of HCT from haploidentical family donors (HFDs) have improved, making it a feasible option for patients lacking an HLA-identical donor. However, data on HFD-HCT for younger patients with SAA is sparse. In this multicenter retrospective study, we evaluated the outcomes of 79 patients undergoing HFD-HCT for SAA. All the patients were heavily pretransfused, the median time to HCT was >12 months, and 67% had failed previous therapies. Conditioning was based on fludarabine (Flu)-cyclophosphamide (Cy)-antithymocyte globulin (ATG)/total body irradiation (TBI) with or without thiotepa/melphalan (TT/Mel). Post-transplantation Cy (PTCy) and calcineurin inhibitors (CNIs)/sirolimus were used as graft-versus-host disease (GVHD) prophylaxis with or without abatacept. The rate of primary graft failure (PGF) was 16.43% overall, lower in patients conditioned with TT/Mel. The incidences of acute and chronic GVHD were 26.4% and 18.9%, respectively. At a median follow-up of 48 months, the overall survival (OS) and event-free survival (EFS) were 61.6% and 58.1%, respectively. Both OS and EFS were better in the TT/Mel recipients and with abatacept as GVHD prophylaxis. On multivariate analysis, the use of abatacept was found to favorably impact the outcome variables, including GVHD and EFS. Our study suggests that PTCy-based HFD-HCT is a reasonable option for young patients with high-risk SAA, in whom optimization of conditioning and GVHD prophylaxis might further improve outcomes. (c) 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available